Why Gene Therapy Is Still So Hard to Manufacture at Scale | Phillip Ramsey
Episode 45
Why is gene therapy still so difficult to manufacture at scale after decades of progress? Phillip Ramsey, Chief Technical Officer at Sangamo Therapeutics, joins BioTalk Unzipped for a candid conversation about one of the central challenges facing advanced therapies: turning extraordinary science into reproducible, scalable medicines. Thank You to Our Sponsors Leucentra - https://leucentra.com/ Inspired by Science. Empowered by IT. Leucentra provides specialized IT consulting and services for life sciences and healthcare, helping organizations use technology more effectively to support innovation. TruTechnologies - https://trutechnologies.ai/ Clinical Trial Execution, Live. TruTechnologies provides live clinical trial execution technology that gives sponsors greater visibility into protocol activities, samples, and study data as they happen. About This Episode Recorded onsite at the AAPS National Biotechnology Conference in Boston, Phillip explains why gene therapy manufacturing has not yet reached the maturity of monoclonal antibody production. As technologies have evolved across retroviral vectors, lentiviral vectors, adenovirus, AAV, lipid nanoparticles, and other advanced modalities, development teams have repeatedly been required to rethink fundamental manufacturing and analytical questions.
Publisher
BioTalk Unzipped
Link
biotalk-unzipped.captivate.fm/episode/gene-therapy-manufacturing-scale-up
Published
August 8, 2026
Duration
11 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
Gregory Austin
BioTalk Unzipped
@biotalkunzipped
#genetherapy #manufacture #phillipramsey #lifesciences #medicine
